ClinicalTrials.gg
RecruitingNCT06940440Updated Oct 21, 2026

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

A Phase 1 interventional study of IFx-Hu2.0 and Pembrolizumab in Advanced Or Metastatic Merkel Cell Carcinoma, sponsored by TuHURA Biosciences, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by TuHURA Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 21, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
1,627th of 1,865
9 · median 43
Started
2026
with 84 others
Phase 1
710 of 2,056
128 open now
Primary completion
2027-04
later than 203 of 541 live
Registered
1,932nd of 2,056
by date

Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 1,627th largest by planned enrollment of the 1,865 interventional ones that give a count, is one of 85 that started in 2026, is one of 710 in phase 1, reaches primary completion later than 203 of the 541 other live ones, and was the 1,932nd registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,056 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult participant (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine participants will receive IFx-Hu2.0 as a visceral/nodal lesion injection followed by pembrolizumab.

03

Conditions studied

  • Advanced Or Metastatic Merkel Cell Carcinoma

Keywords

  • Metastatic
  • Advanced
  • Merkel Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. equal to or greater than six months.
  3. (ECOG) Performance Status \< 2.
  4. Has as defined by v1.1
  5. Must be recurrent and/or unresectable Stage III or Stage IV American Joint Committee on Cancer (AJCC) (8th edition) and have confirmed advanced or Merkel cell carcinoma

    a. Must have at least one deep-seated visceral/nodal greater than 3 mm in its longest diameter

  6. Subject should be CPI naïve i.e., no prior therapy with CPI including but not limited to Pembrolizumab, avelumab, ipilimumab, nivolumab.
  7. Tumor tissue from an archival core or resected site of disease must be provided for biomarker analyses. If archival tissue is not available, then a new biopsy should be performed.
  8. Adequate hematological, hepatic, and renal function according to laboratory ranges and medical criteria defined within the study protocol.

Exclusion criteria

Exclusion Criteria

  1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with protocol requirements.
  2. Subjects with active , with the exception of treated brain metastases that have imaging proving stability at least 4 weeks after treatment, no new , and not requiring .
  3. Subjects with recurrent resectable MCC
  4. Subjects who have received prior systemic chemotherapy
  5. Pregnant or breastfeeding females and females desiring to become pregnant or breastfeed within the timeframe of this study.
  6. Active, known, or suspected disease. Potential subjects with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. Low grade autoimmune toxicity is NOT an exclusion under this criterion.
  7. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other medications within 14 days of IFx-Hu2.0 administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    IFx-Hu2.0

    Participants will receive IFx-Hu2.0 0.1 mg as a visceral/nodal lesion injection in a single lesion once per week for 3 consecutive weeks. At the discretion of the investigator, the same lesion will be injected at each injection visit, unless the initially injected lesion is no longer suitable for injection; alternatively, another lesion may be injected if the participant has other visceral/nodal lesions that meet the protocol injection criteria and are considered safe to inject. Pembrolizumab (200 mg) will be administered IV at Visit 1 (within 48 hours after the first IFx-Hu2.0 injection) and then every 3 weeks for approximately 6 months until disease progression or unacceptable immune-related toxicity.

    Drug: IFx-Hu2.0 · Drug: Pembrolizumab

Interventions

  • Therapeutic Classification: • Innate immune agonist Route of Administration: • Intralesional

    Also known as: pAc/emm55

  • Therapeutic Classification: • Immunotherapy (Immune checkpointinhibitor) Route of administration: • Intravenous (IV) infusion

    Also known as: KEYTRUDA

06

What researchers measure

Primary outcomes

  1. Safety

    Safety is defined as the absence of any grade 3-5, treatment-related Adverse Events (AEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from first injection Day 1 to 28-day follow-up after the final dose of IFx-Hu2.0.

    Time frame: 28 days from last dose of IFx-Hu2.0

  2. Feasibility

    Feasibility is defined as the ability to treat ≥50% of participants (i.e. 5/9) with all 3 doses of intralesional IFx-Hu2.0 in the per-protocol analysis.

    Time frame: 28 days from last dose of IFx-Hu2.0

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 15 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Oct 2025 → Jan 2026 and primary completion May 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 23, 2025
StartActual
Jan 27, 2026was Oct 2025
Primary completionEst.
Apr 2027was May 2026
CompletionEst.
May 31, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2025→Jan 27, 2026 (actual)
Oct 21, 2026
Primary completion
May 31, 2026→Apr 2027
Oct 21, 2026
Eligibility
2 inclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedActive disease measurable by CT or MRI, measurable lesions are lesions that can be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded).
  • AddedHas measurable disease as defined by RECIST v1.1
  • EditedMust be recurrent and/or unresectable Stage III or Stage IV American Joint Committee on Cancer (AJCC) (8th edition) and have histologically confirmed advanced or metastatic Merkel cell carcinoma
  • EditedMust have at least one deep-seated visceral injectable lesion equal to or/nodal greater than 3 mm in its longest diameter
Oct 21, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionFeasibility: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Start date Oct 2025→Jan 27, 2026 (now actual)
    Primary completion May 31, 2026→Apr 2027
    Eligibility 2 inclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedActive disease measurable by CT or MRI, measurable lesions are lesions that can be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded).
    • AddedHas measurable disease as defined by RECIST v1.1
    • EditedMust be recurrent and/or unresectable Stage III or Stage IV American Joint Committee on Cancer (AJCC) (8th edition) and have histologically confirmed advanced or metastatic Merkel cell carcinoma
    • EditedMust have at least one deep-seated visceral injectable lesion equal to or/nodal greater than 3 mm in its longest diameter
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionFeasibility: how it is measured was reworded
    + 4 other changes: identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06940440
Lead sponsor
TuHURA Biosciences, Inc.
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Jan 27, 2026
Primary completion
Apr 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

James Bianco, MD
Contact
jbianco@tuhurabio.com
8138756600 ext. 104
Andrew S Brohl, MD
principal investigator · Collaborator

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0

Start the discussion